Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 4/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.54 |
| ▸ | GNRHR | P30968 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349954 | 1.00 | TFPI (0.55) | TFPICXCR4AGTR1GNRHRAGTR2 | |
| SCHEMBL30788346 | 0.83 | TFPI (0.56) | TFPICXCR4 | |
| SCHEMBL30788354 | 0.83 | TFPI (0.55) | TFPICXCR4 | |
| SCHEMBL30788340 | 0.83 | F2 (0.59) | TFPICXCR4CALCRF2HCRTR1 | |
| SCHEMBL30788343 | 0.81 | F2 (0.57) | TFPICXCR4CALCRF2HCRTR1 | |
| SCHEMBL30788336 | 0.81 | F2 (0.57) | TFPICXCR4CALCRF2HCRTR1 | |
| SCHEMBL30788361 | 0.81 | NMUR2 (0.56) | TFPI | |
| SCHEMBL30954812 | 0.81 | NPY2R (0.59) | TFPICXCR4RAMP3CALCR | |
| SCHEMBL30788353 | 0.81 | CALCR (0.60) | CXCR4CALCRF2HCRTR1HCRTR2 | |
| SCHEMBL30788360 | 0.80 | F2 (0.55) | TFPICXCR4CALCRF2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115948346-B | Hybridoma cell strain capable of stably secreting anti-conotoxin mu-KIIIA-CTX monoclonal antibody | 福建农林大学 | 2024-11-22 | — | — | CN | claimed |
| CN-115948346-A | Hybridoma cell strain capable of stably secreting anti-conotoxin mu-KIIIA-CTX monoclonal antibody | 福建农林大学 | 2023-04-11 | — | — | CN | claimed |
| CN-115806609-A | Alpha-conotoxin MI-protein coupling antigen and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-03-17 | — | — | CN | claimed |
| CN-119954923-A | New mu-type conotoxin peptide, pharmaceutical composition and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119912548-A | Mu-type conotoxin peptide mutant, pharmaceutical composition and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119912547-A | Mu-type conotoxin peptide, polynucleotide for encoding same and application thereof | 苏州华肽鹏诚生物制造有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119684424-A | Mu-type conotoxin peptide, polynucleotide coded by mu-type conotoxin peptide and application of mu-type conotoxin peptide | 深圳肽盛生物科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119529050-A | Mu-type conotoxin peptide [ Asn ]17,Arg6] -DR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119504969-A | Mu-type conotoxin peptide [ Asn ]17,Arg5] -DR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119462881-A | Mu-type conotoxin peptide, pharmaceutical composition and application thereof | 深圳肽盛生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119409793-A | Mu-conotoxin peptide [ Ser ]17,Tyr11] -DR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118146336-A | Novel mu-conotoxin peptide dR-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146338-A | Novel mu-conotoxin peptide dK-mu-CnIIIC and application thereof | 深圳肽盛生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-115948346-A | Hybridoma cell strain capable of stably secreting anti-conotoxin mu-KIIIA-CTX monoclonal antibody | 福建农林大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-115948346-A | Hybridoma cell strain capable of stably secreting anti-conotoxin mu-KIIIA-CTX monoclonal antibody | 福建农林大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-115948346-A | Hybridoma cell strain capable of stably secreting anti-conotoxin mu-KIIIA-CTX monoclonal antibody | 福建农林大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-115806609-A | Alpha-conotoxin MI-protein coupling antigen and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-03-17 | — | — | CN | disclosed |
| CN-115702161-A | Peptide compositions and methods for inhibiting nicotinic acetylcholine receptor activity | 格罗制药公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-114269384-A | Compositions for modulating the effects of botulinum neurotoxins | 法斯托克斯制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | TFPI 2394/4885CXCR4 1494/4885AGTR1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.